These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

241 related articles for article (PubMed ID: 4895579)

  • 1. [Steroid spirolactones--antagonists of mineralocorticoids].
    Linèt O
    Cesk Farm; 1969 Jun; 18(4):218-26. PubMed ID: 4895579
    [No Abstract]   [Full Text] [Related]  

  • 2. Azolimine: a nonsteroidal antagonist of the effects of mineralocorticoids on renal electrolyte excretion.
    Gussin RZ; Ronsberg MA; Stokey EH; Cummings JR
    J Pharmacol Exp Ther; 1975 Oct; 195(1):8-15. PubMed ID: 1181406
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Evaluation of the therapeutic effectiveness of a saluretic of the polythiazide type (Renese)].
    Anghelescu L; Băcanu G; Turcanu V; Bartl F
    Med Interna (Bucur); 1969 Feb; 21(2):205-10. PubMed ID: 5780237
    [No Abstract]   [Full Text] [Related]  

  • 4. Mineralocorticoids and sweat gland function.
    Gibiński K; Giec L; Nowak S; Kokot F
    Acta Biol Med Ger; 1970; 25(1):201-5. PubMed ID: 5489678
    [No Abstract]   [Full Text] [Related]  

  • 5. Mespirenone and other 15,16-methylene-17-spirolactones, a new type of steroidal aldosterone antagonists.
    Losert W; Bittler D; Buse M; Casals-Stenzel J; Haberey M; Laurent H; Nickisch K; Schillinger E; Wiechert R
    Arzneimittelforschung; 1986 Nov; 36(11):1583-600. PubMed ID: 3028435
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Potassium prorenoate: a new steroidal aldosterone antagonist.
    Hofmann LM; Chinn LJ; Pedrera HA; Krupnick MI; Suleymanov OD
    J Pharmacol Exp Ther; 1975 Aug; 194(2):450-6. PubMed ID: 1151770
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The effect of adrenal steroids on stool composition, as revealed by in vivo dialysis of faeces.
    Charron RC; Leme CE; Wilson DR; Ing TS; Wrong OM
    Clin Sci; 1969 Aug; 37(1):151-67. PubMed ID: 5822526
    [No Abstract]   [Full Text] [Related]  

  • 8. [Therapy of heart insufficiency using aldosterone antagonists].
    Krauss J
    Z Allgemeinmed; 1973 Jul; 49(21):989-91. PubMed ID: 4756071
    [No Abstract]   [Full Text] [Related]  

  • 9. Sodium retention in heart failure and cirrhosis: potential role of natriuretic doses of mineralocorticoid antagonist?
    Bansal S; Lindenfeld J; Schrier RW
    Circ Heart Fail; 2009 Jul; 2(4):370-6. PubMed ID: 19808361
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Hyperaldosteronism and the use of aldactone in cardiac insufficiency].
    Korochkin IM; Matveeva IV; Sidorenko BA; Arshakuni RO
    Kardiologiia; 1968 Dec; 8(12):74-81. PubMed ID: 5736746
    [No Abstract]   [Full Text] [Related]  

  • 11. [Role of aldosterone in the pathogenesis of cardiac insufficiency (review of the literature)].
    Vinogradov AV; Sycheva IM
    Kardiologiia; 1967 Feb; 7(2):89-93. PubMed ID: 4884838
    [No Abstract]   [Full Text] [Related]  

  • 12. 3- (16Beta,17beta-dihydroxy-3-oxoandrost-4-en-17alpha-yl) propionic acid gamma-lactone, its preparation and antimineralocorticoid activity.
    Chinn LJ; Hofmann LM
    J Med Chem; 1973 Jul; 16(7):839-43. PubMed ID: 4725930
    [No Abstract]   [Full Text] [Related]  

  • 13. [Anti-aldosterone therapy in cirrhosis of the liver with ascites].
    Loginov AS; Berezov VM
    Sov Med; 1967 Feb; 30(2):39-42. PubMed ID: 5597952
    [No Abstract]   [Full Text] [Related]  

  • 14. [Mefruside in clinical practice: activity and mechanism of action].
    Perpignano G; Busilacchi M; Verzetti G
    Clin Ter; 1969 May; 49(4):337-63. PubMed ID: 5795021
    [No Abstract]   [Full Text] [Related]  

  • 15. [Use of aldactone and veroshpiron in complex therapy of patients with circulation disorders].
    Bezborod'ko BN; Shekhunova MI; Selivonenko VG
    Ter Arkh; 1973 Jan; 45(1):84-6. PubMed ID: 4770028
    [No Abstract]   [Full Text] [Related]  

  • 16. Non-tumorous "primary" aldosteronism. I. Type relieved by glucocorticoid (glucocorticoid-remediable aldosteronism).
    Salti IS; Stiefel M; Ruse JL; Laidlaw JC
    Can Med Assoc J; 1969 Jul; 101(1):1-10. PubMed ID: 5793351
    [No Abstract]   [Full Text] [Related]  

  • 17. [Sodium-potassium ratio and electrical potential of colon in the screening of hyperaldosteronism (author's transl)].
    Pessina AC; Corgnati A; Dal Palù C
    G Ital Cardiol; 1974; 4(2):167-72. PubMed ID: 4838120
    [No Abstract]   [Full Text] [Related]  

  • 18. [Aldosterone and aldosterone antagonists in surgery].
    Oelert H
    Anaesthesist; 1971 Jun; 20(6):205-11. PubMed ID: 4943021
    [No Abstract]   [Full Text] [Related]  

  • 19. Spirolactones: clinical and pharmacologic studies.
    Corvol P; Claire M; Rafestin-Oblin ME; Michaud A; Roth-Meyer C; Menard J
    Adv Nephrol Necker Hosp; 1977; 7():199-215. PubMed ID: 208407
    [No Abstract]   [Full Text] [Related]  

  • 20. [Effect of spironolactone on the excretion of sodium and potassium in the saliva in secondary hyperaldosteronism].
    Vancura P
    Cas Lek Cesk; 1969 Mar; 108(10):308-9. PubMed ID: 5775579
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 13.